佐力药业9月24日获融资买入3806.29万元，融资余额5.66亿元

Core Insights - Zhaoli Pharmaceutical's stock rose by 3.02% on September 24, with a trading volume of 317 million yuan, indicating positive market sentiment [1] - The company reported a net financing outflow of 11.47 million yuan on the same day, with a total financing and securities balance of 567 million yuan, suggesting a high level of trading activity [1] - As of June 30, 2025, Zhaoli Pharmaceutical achieved a revenue of 1.599 billion yuan, reflecting a year-on-year growth of 11.99%, and a net profit of 374 million yuan, up 26.16% year-on-year [2] Financing and Trading Activity - On September 24, Zhaoli Pharmaceutical had a financing buy-in of 38.06 million yuan, with a financing balance of 566 million yuan, accounting for 4.46% of its market capitalization [1] - The company’s financing balance is above the 70th percentile of the past year, indicating a relatively high level of leverage [1] - The short-selling activity on the same day included a repayment of 2,400 shares and a sale of 7,900 shares, with a short-selling balance of 121.75 million yuan, exceeding the 90th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, 2025, Zhaoli Pharmaceutical had 38,600 shareholders, an increase of 0.92% from the previous period, with an average of 15,627 circulating shares per shareholder, a decrease of 0.91% [2] - The company has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed over the last three years [3] - New institutional shareholders include China Europe Responsibility Investment Mixed A and Innovation Drug, both entering the top ten circulating shareholders [3]